Literature DB >> 10364376

Persistent infection of rhesus macaques by the rev-independent Nef(-) simian immunodeficiency virus SIVmac239: replication kinetics and genomic stability.

A S von Gegerfelt1, V Liska, N B Ray, H M McClure, R M Ruprecht, B K Felber.   

Abstract

We generated previously a Nef(-), replication-competent clone of SIVmac239 in which the Rev protein and the Rev-responsive element were replaced by the constitutive transport element (CTE) of simian retrovirus type 1 (A. S. von Gegerfelt and B. K. Felber, Virology 232:291-299, 1997). In the present report, we show that this virus was able to infect and replicate in rhesus macaques. The Rev-independent Nef(-) simian immunodeficiency virus induced a persistent humoral immune response in all monkeys, although viral loads were very low. Upon propagation in the monkeys, the genotype remained stable and the virus retained its in vitro growth characteristics. The infected monkeys showed normal hematological values and no signs of disease at more than 18 months post-virus exposure. Therefore, replacement of the essential Rev regulation by the CTE generated a virus variant that retained its replicative capacity both in vitro and in vivo, albeit at low levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364376      PMCID: PMC112685     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  A formalin-fixed whole SIV vaccine induces protective responses that are cross-protective and durable.

Authors:  M Murphey-Corb; S Ohkawa; B Davison-Fairburn; L N Martin; G B Baskin; A J Langlois; M McIntee; O Narayan; M B Gardner
Journal:  AIDS Res Hum Retroviruses       Date:  1992-08       Impact factor: 2.205

2.  Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.

Authors:  D P Burns; R C Desrosiers
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

3.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.

Authors:  D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

4.  Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS.

Authors:  J Overbaugh; L M Rudensey; M D Papenhausen; R E Benveniste; W R Morton
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

5.  The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function.

Authors:  C Tabernero; A S Zolotukhin; A Valentin; G N Pavlakis; B K Felber
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Continuous propagation of RRE(-) and Rev(-)RRE(-) human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes.

Authors:  A S Zolotukhin; A Valentin; G N Pavlakis; B K Felber
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent.

Authors:  M Bray; S Prasad; J W Dubay; E Hunter; K T Jeang; D Rekosh; M L Hammarskjöld
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

8.  Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop.

Authors:  Z Chen; P Telfier; A Gettie; P Reed; L Zhang; D D Ho; P A Marx
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

Authors:  T W Baba; Y S Jeong; D Pennick; R Bronson; M F Greene; R M Ruprecht
Journal:  Science       Date:  1995-03-24       Impact factor: 47.728

10.  Clinical features and predictive markers of disease progression in cynomolgus monkeys experimentally infected with simian immunodeficiency virus.

Authors:  P Putkonen; E E Kaaya; D Böttiger; S L Li; C Nilsson; P Biberfeld; G Biberfeld
Journal:  AIDS       Date:  1992-03       Impact factor: 4.177

View more
  5 in total

1.  Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques.

Authors:  Agneta S von Gegerfelt; Vladimir Liska; Pei-Lin Li; Harold M McClure; Kyoji Horie; Filomena Nappi; David C Montefiori; George N Pavlakis; Marta L Marthas; Ruth M Ruprecht; Barbara K Felber
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus.

Authors:  Agneta von Gegerfelt; Antonio Valentin; Candido Alicea; Koen K A Van Rompay; Marta L Marthas; David C Montefiori; George N Pavlakis; Barbara K Felber
Journal:  J Immunol       Date:  2010-08-11       Impact factor: 5.422

3.  Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted.

Authors:  Y Guan; J B Whitney; M Detorio; M A Wainberg
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs.

Authors:  David O Willer; Yongjun Guan; Mark A Luscher; Bing Li; Rick Pilon; Jocelyn Fournier; Monique Parenteau; Mark A Wainberg; Paul Sandstrom; Kelly S MacDonald
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103

5.  Live attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaques.

Authors:  Siddappa N Byrareddy; Mila Ayash-Rashkovsky; Victor G Kramer; Sandra J Lee; Mick Correll; Francis J Novembre; Francois Villinger; Welkin E Johnson; Agneta von Gegerfelt; Barbara K Felber; Ruth M Ruprecht
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.